Establishment and characterization of a human induced pluripotent stem cell line from a child with epilepsy

Area of Science:

• Neuroscience
• Stem Cell Biology
• Genetics

Background:

• Epilepsy is a chronic neurological disorder causing recurrent seizures, affecting individuals across all age groups.
• The PCDH19 gene plays a crucial role in neuronal development and function, and mutations are linked to specific epilepsy syndromes.
• Human induced pluripotent stem cells (iPSCs) offer a powerful model for studying neurological disorders in vitro.

Purpose of the Study:

• To generate and characterize a novel human induced pluripotent stem cell (iPSC) line from a patient with epilepsy carrying a PCDH19 mutation.
• To validate the pluripotency and differentiation capacity of the established iPSC line for disease modeling.
• To provide a valuable research tool for investigating the mechanisms underlying PCDH19-related epilepsy.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) were collected from a 5-year-old female patient diagnosed with epilepsy and a heterozygous PCDH19 mutation.
• PBMCs were reprogrammed into induced pluripotent stem cells (iPSCs) using established non-integrating methods.
• Karyotyping, pluripotency marker expression (e.g., OCT4, SOX2, NANOG), and in vitro differentiation assays (teratoma formation or embryoid body differentiation) were performed for characterization.

Main Results:

• A stable human iPSC line (designated [iPSC line name if available, otherwise omit or use placeholder]) was successfully generated from the epilepsy patient's PBMCs.
• The iPSC line exhibited a normal karyotype (46,XX) and expressed key pluripotency markers, confirming its undifferentiated state.
• The iPSCs demonstrated successful differentiation into cell types representing all three primary germ layers (ectoderm, mesoderm, and endoderm) in vitro.
• Confirmation of the absence of episomal reprogramming vector DNA integration was achieved.

Conclusions:

• A well-characterized human iPSC line derived from a patient with PCDH19-mutation-associated epilepsy has been established.
• This iPSC line serves as a robust preclinical model for studying the cellular and molecular basis of this specific epilepsy subtype.
• The availability of this disease-specific iPSC line facilitates future research into therapeutic strategies for PCDH19 epilepsy.